News Flash Update: Scan Clear!! October 15th, 9:00 EST
Deb has just called to say that her MRI today was completely clear. The spots from the previous MRI have "disappeared" and no other anomolies were seen. Great news! Deb and her father Bob will be celebrating and Deb will post an update shortly.
10 comments:
Yippee! The CT posse knew it would be clear. Keep on doing what you're doing because it is obviously working. Love, Amy, Carrie, Lisa, Anita, Joann and Jana.
FANTASTIC news, Deb!!! I'm so happy for you! Have a great time celebrating with your dad!
Love ya!
Donna:)
Awesome, awesome news!!! That is wonderful! Enjoy your celebration with your dad!!
Now if the Red Sox would win, all would be good!
Love - Galynn
Debbie,
This is amazing news! I am so happy for you!!
Much love,
Alicyn
excellent, excellent, excellent
what else to say? (except that the Sox had better win tonight)
Barbara
Debbie what awesome news!!! Hope you and your Dad have a great time celebrating. Looking forward to the next update.
Love you, Larry and Priscilla
Yet another MRI that went as we expected. FABULOUS. We love disappearing brain spots. Kiss your daddy for me.
Molster
Hi Deb,
YEAH!! This is the GREAT news I was hoping for after I saw your previous recent posts. I am thrilled for you.
And, hooray for short guys!! I've been out with a few short guys recently (nothing serious).....claiming 5'8" but actually 5'5" to 5'6." I have not run into 5'4" yet. Funny how the guys have a different way of measuring height than we do. I hope things continue to go well for you and Charlie. I agree, there are some wonderful short guys.
Keep celebrating!!
Warm healing beacons,
Bea
Wooooohoooooooo, Debbie!!! Great Great news! Have fun with Bubbie.....keep up the fabulous work, we love you!
Love ya,
Nikki
Results from a Phase II study showed that Genentech's Avastin (bevacizumab), in combination with irinotecan, increased survival rates in patients with recurrent glioblastoma multiforme. The findings are published in the current issue of the Journal of Clinical Oncology.
In the trial, a total of 35 patients with recurrent glioblastoma multiforme received a combination of Avastin plus irinotecan. The findings showed that six-month progression-free survival among all patients was 46 percent, and six-month overall survival was 77 percent. Additionally, 20 of the patients in the trial experienced at least a partial response to the combination therapy, the results demonstrated.
The researchers, who noted that the current prognosis for this patient group is a median survival of three to six months, commented that the study data represent "improved outcomes for patients with this cancer." Lead researcher, James Vredenburgh added that "there is no standard treatment that improves survival, so this is extremely promising."
Post a Comment